Antiepileptic effect of nefiracetam on kainic acid-induced limbic seizure in rats

Epilepsy Research

Volumn 39, Issue 3, 2000, Pages 221-228

  Hashizume, Kiyotaka ^a   Kunimoto, Masayuki ^a   Maeda, Takahiro ^a   Tanaka, Tatsuya ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Antiepileptic effect; Cerebral metabolism; Electroencephalogram; Experimental epilepsy; Kainic acid; Nefiracetam

Indexed keywords

DEOXYGLUCOSE; KAINIC ACID; NEFIRACETAM;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUTORADIOGRAPHY; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BRAIN CHEMISTRY; ELECTROPHYSIOLOGY; ELECTROSHOCK; EXCITATORY AMINO ACID AGONISTS; GLUCOSE; KAINIC ACID; LIMBIC SYSTEM; MALE; PYRROLIDINONES; RATS; RATS, WISTAR; SEIZURES;

EID: 0034029105     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00099-1     Document Type: Article

References (36)

1. Abe E., Murai S., Saito H. et al. Effects of nefiracetam on deficits in active avoidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice. J. Neural. Trans. General. Sec. 95:1994;179-193.
2. Ben-Ari Y., Lagowska J., Tremblay E., Le Gal La Salle G. A new model of focal status epilepticus: intra-amygdaloid application of kainic acid elicits repetitive secondarily generalized convulsive seizures. Brain Res. 163:1979;176-179.
3. Berger M.L., Charton G., Ben-Ari Y. Effect of seizures induced by intra-amygdaloid kainic acid on kainic acid binding sites in rat hippocampus and amygdala. J. Neurochem. 47:1986;720-727.
4. Clifford D.B., Olney J.W., Benz A.M., Fuller T.A., Zorumski C.F. Ketamine, phencyclidine and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia. 31:1990;382-390.
5. Croisile B., Trillet M., Fondarai J. et al. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology. 43:1993;301-305.
6. Gouliaev A.H., Senning A. Piracetam and other structurally related nootropics. Brain Res.-Brain Res. Rev. 19:1994;180-222.
7. Gower A.J., Noyer M., Verloes R., Gobert J., Wulfert E. ucb L059, a novel anticonvulsant: pharmacological profile in animals. Eur. J. Pharmacol. 222:1992;193-203.
8. Hashizume K., Tanaka T., Yonemasu Y. Change in cerebral glucose metabolism during limbic seizures elicited from lateral septal nucleus. Epilepsy Res. 30:1998a;167-176.
9. Hashizume K., Tanaka T. Multiple subpial transection in kainic acid-induced focal cortical seizure. Epilepsy Res. 32:1998b;389-399.
10. Huang C.S., Ma J.Y., Marszalec W., Narahashi T. Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons. Neuropharmacology. 35:1996;1251-1261.
11. Kitano Y., Makino M., Usui C. et al. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Arzneim-Forsch./Drug Res. 44:1994;199-210.
12. Loscher W., Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232:1993;147-158.
13. Loscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Therapeutics. 284:1998;474-479.
14. Lothman E.W., Collins R.C. Kainic acid induced limbic seizures: metabolic, behavioral, electroencephalographic and neuropathological correlates. Brain Res. 218:1981;299-318.
15. Luthman J., Lindqvist E., Dell'Anna E. et al. Effects of DM-9384, a pyrrolidone derivative, on ischemia-induced changes in the central monoamine systems. Pharmacol. Biochem. Behav. 41:1992;231-234.
16. Nabeshima T., Tohyama K., Murase K. et al. Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic receptors induced by cycloheximide. J. Pharmacol. Exp. Therapeut. 257:1991;271-275.
17. Nishizaki T., Matsuoka T., Nomura T. et al. Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol. Pharmacol. 53:1998;1-5.
18. Noyer M., Gillard M., Matagne A., Henichart J.-P., Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286:1995;137-146.
19. Obeso J.A., Artieda J., Quinn N. et al. Piracetam in the treatment of different types of myoclonus. Clin. Neuropharmacol. 11:1988;529-536.
20. Olney J.W. Kainic acid and other excitotoxins: a comparative analysis. Adv. Biochem. Psychopharm. 27:1981;375-384.
21. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A stereotaxic atlas of the rat brain. 1979;Plenum Press, New York.
22. Richardson A.E., Bereen F.J. Effect of piracetam on level of consciosness after neurosurgery. Lancet. 2:1977;1110-1111.
23. Sakurai T., Hatanaka S., Tanaka S. et al. Protective effect of DM-9384, a novel pyrrolidone derivative, against experimental cerebral anoxia. Jpn. J. Pharmacol. 54:1990;33-43.
24. Sakurai T., Kato T., Mori K. et al. Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci. Lett. 246:1998;69-72.
25. Sakurai T., Ojima H., Yamasaki T., Kojima H., Akashi A. Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats. Jpn. J. Pharmacol. 50:1989;47-53.
26. Singh, P., Sharief, M.K., Sander, J.W.A.S., 1992. A pilot study of the efficacy and tolerability of L059 in patients with refractory epilepsy [abstract]. Seizure 1 Suppl A p7/46.
27. Sokoloff L., Reivich M., Kennedy C. et al. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28:1977;897-916.
28. Sperk G., Lassmann H., Baran H. et al. Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience. 10:1983;1301-1315.
29. Sugawara T., Kato M., Furuhama K. et al. Single dose toxity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs. Arzneim-Forsch. Drug Res. 44:1994;211-213.
30. Takano K., Tanaka T., Fujita T., Nakai H., Yonemasu Y. Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats. Epilepsia. 36:1995;644-648.
31. Tanaka S., Kondo S., Tanaka T., Yonemasu Y. Long-term observation of rats after unilateral intra-amygdaloid injection of kainic acid. Brain Res. 463:1988;163-167.
32. Tanaka S., Sako K., Tanaka T., Nishihara I., Yonemasu Y. Uncoupling of local blood flow and metabolism in the hippocampal CA3 in kainic acid-induced limbic seizure status. Neuroscience. 36:1990;339-348.
33. Tanaka T., Tanaka S., Fujita T. et al. Experimental complex partial seizures induced by a microinjection of kainic acid into limbic structures. Prog. Neurobiol. 36:1992;317-334.
34. Watabe S., Yamaguchi H., Ashida S. DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex. Eur. J. Pharmacol. 238:1993;303-309.
35. Yoshii M., Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res. 642:1994;123-131.
36. Yoshii M., Watabe S., Sakurai T., Shiotani T. Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav. Brain Res. 83:1997;185-188.